ProMIS Neurosciences Previews Interim Data from Alzheimer’s Trial — ProMIS Neurosciences Inc.

Event summary

ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss six-month blinded interim data from the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer’s patients.
The trial evaluates safety, biomarker trends, and pharmacokinetics across three dosing cohorts (5, 10, and 20 mg/kg) with 144 participants enrolled.
Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner will join ProMIS executives to analyze the data.
PMN310 is a humanized IgG1 monoclonal antibody targeting toxic amyloid-beta oligomers, granted Fast Track Designation by the FDA in July 2025.

The big picture

ProMIS’s webinar comes amid intense competition in Alzheimer’s therapeutics, where selective targeting of toxic oligomers is a differentiating strategy. The trial’s design and Fast Track status underscore the urgency to address unmet needs in early-stage Alzheimer’s treatment. Success here could position PMN310 as a safer alternative to existing amyloid-targeting therapies.

What we're watching

Biomarker Validation: How the blinded aggregate biomarker data will influence confidence in PMN310’s mechanism of action.
Safety Profile: Whether PMN310’s selectivity for toxic oligomers reduces ARIA risks compared to plaque-binding antibodies.
Regulatory Momentum: The pace at which ProMIS can advance PMN310 toward Phase 2 trials based on interim results.